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ABSTRACT
Background: Whether all the small (ø≤20mm) non-functional pancreatic 
neuroendocrine neoplasms (pNENs) should be routinely resected is unclear.
Aim: To assess the overall survival (OS) and progression-free survival (PFS) of 
patients with small pNENs, followed-up with different management options.
Material and methods: Between 2007-2014, 51 patients were newly diagnosed 
with pNEN. 15 patients with pNENs ø ≤20 mm underwent an intensive follow-
up at 3-month intervals during the first year and then every 6 months (FU pNEN 
group). They were all at TNM stage I, except for one patient at stage IIA. 21 patients 
underwent surgical resection (SR pNEN group): 2 patients were at TNM stage I, 9 
IIA, one IIIB, 9 IV. 15 patients received systemic therapy (ST pNEN group) due to 
advanced disease or contraindications to surgery: 5 were at stage IIA, 2 IIB, 8 IV.
Results: The median follow-up for the entire cohort was 50 months. Survival 
was similar in the FU and SR pNEN groups, but significantly worst in the ST pNEN 
patients (log-rank test P <0.05). The 4-year survival rate was 100% in the FU pNEN 
group, 90.5% among the SR pNEN patients, 61% for the ST pNEN ones (p <0.0001). 
The disease remained stable in all but one patient in the FU pNEN group, whereas six 
patients in the SR group and five in the ST group showed disease progression.
Conclusions: The “wait-and-watch” approach to early-stage small pNENs appears 
to be safe although further studies are needed to confirm these results in larger 
cohorts of patients.
INTRODUCTION
Pancreatic neuroendocrine neoplasms (pNENs) 
are rare neoplasms, even if their incidence is on the 
increase worldwide [1–3] as well documented over the 
last two decades [4]. As recently pointed out by SEER 
the incidence of pNENs with a ≤ 2 cm size has increased 
by 710.4% (with an annual 12.8% change) over 22 years 
[5]. Such a fact may result from the increasing use of 
endoscopic ultrasound, which implies the greater ability 
to detect small pNENs.
PNENs represent ca. 2% of all pancreatic tumors 
and may be either non-functioning (50% to 90%) or 
functioning (10% to 50%). PNENs are characterized by 
great biological variability. It has been hypothesized that 
larger neoplasms have a greater potential for aggressive 
behavior, whereas smaller (ø ≤2 cm), low-grade, non-
functioning tumors usually display a more benign 
behavior, with slow growth and an overall good prognosis 
[5]. However, nodal and distant metastases as well as 
disease recurrence have been documented with regard to 
small tumors, suggesting that such tumors too may have a 
malignant potential [5–9]. On the other hand, good overall 
survival (up to 100% after 5 years) and little impact on 
survival from small pNENs, incidentally discovered, have 
been described [10–11]. In a recent bi-institutional study 
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Gaujoux et al. [12] observed that none of their 46 patients 
with small incidentally discovered pNENs had developed 
distant or nodal metastases after a median follow-up of 34 
months and an average number of serial imaging sessions 
at 4. In 6 patients (13%) a ≥20% increase in size was 
observed, but no patient nor tumor characteristics were 
found to be significant predictors of tumor growth.
Several attempts to determine factors that are 
predictive of tumor growth, nodal or distant metastases, 
or survival have been made, with inconsistent results 
until now.
With these areas of uncertainty in mind, surgical 
resection has always been considered as the most 
appropriate management option for these tumors because 
of: their heterogeneous, often unpredictable biological 
behavior, the lack of specific prognostic factors and data 
from the literature suggesting a positive effect of surgery 
on overall pNEN survival. In a retrospective study on 380 
patients Sharpe et al. [13] demonstrated that with regard 
to non-functional ø ≤2 cm sized pNENs surgical resection 
delivers a survival benefit, with a five-year overall survival 
(OS) of 82.2% for patients who underwent surgery and 
34.3% for patients who underwent observation only. 
Noteworthy, the tumor size and margin status were not 
predictors of survival, whilst lymph node positivity was 
found to be associated with a decreased 5-year OS. On 
the other hand, a relevant morbidity (<5%) and mortality 
(40%–50%) is associated with pancreatic resection [14–
15] and long-term exocrine and endocrine pancreatic 
insufficiency may affect the quality of life [16].
Despite a substantial controversy regarding the 
best management options for pNENs smaller than 2 cm, 
the European Neuroendocrine Tumor Society (ENETS) 
guidelines now recommend a “wait and see” policy in 
selected patients with small asymptomatic pNENs [17] in 
view of the slow growth of such tumors and good overall 
survival [10]. This strategy has gained acceptance for 
multiple endocrine neoplasia type 1 (MEN-1) patients 
[18–20] and some retrospective series have validated 
this approach also with regard to sporadic incidentally 
identified non-functioning pNENs smaller than 2 cm. Lee 
et al. [21] observed a nearly 50% risk of complications 
among the 57 patients who underwent surgery. The 
remaining 77 patients were conservatively managed and 
they were all free of disease progression, suggesting that 
non-operative management may be advocated for carefully 
selected pNENs when serial imaging demonstrates 
minimal or no growth without suspicious features.
However, the currently recommended conservative 
approach to small pNENs is based on under-powered 
and retrospective series and the resection of small, non-
functioning tumors has not been compared to date with the 
conservative approach in prospective trials.
Based on the above reported findings, our present 
prospective series was aimed at evaluating both OS and 
progression-free survival (PFS) of patients with small 
pNENs evaluated at a single Institution according to the 
different clinical management options.
RESULTS
The median follow-up for the entire cohort was 50 
months (range 2-84). The overall 4-year survival rate was 
86%. At the end of the study, 44 patients (86%) were still 
alive. Of the 7 patients (14%) who had died, 6 died of 
disease-related causes, whereas one patient passed away 
for unrelated causes.
The OS was similar in the FU pNEN and SR pNEN 
groups, but, as expected, it was significantly worse in the 
ST pNEN group (log-rank test p=0.018 for the overall 
comparison; p=0.023 for the comparison between the ST 
pNEN and the FU pNEN groups, adjusted for multiple 
comparisons) (Figure 1). The 4-year survival rate was 
100% in the FU pNEN group, 90.5 % in the SR pNEN 
group and 61% in the ST pNEN one, respectively (p 
<0.0001 at χ2 test).
Progression-free survival (PFS) did not differ among 
the three groups (log-rank test p=0.304), even if disease 
remained stable in all but one FU patients (7%), whereas 
six patients (28%) in the SR group and five (31%) in the 
Figure 1: Overall survival (OS) and progression-free survival (PFS) of patients who have undergone follow-up (FU), 
surgical resection (SR) and systemic therapy (ST), respectively.
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ST group showed disease progression after 51 months 
follow-up.
With regard to the FU pNEN group, the patient with 
disease progression was a female with a MEN-1 syndrome 
and showed evidence of lung and nodal metastases 
during follow-up, 19 months after the initial diagnosis; 
no surgical therapy was planned after the evidence of 
disease progression and she underwent medical therapy by 
somatostatin analogues (SSAs) with disease stabilization.
Among the 21 patients of SR pNEN group we 
observed a nearly 50% of complications: 5 mild (post-
surgical infection), 3 moderate (pancreatic fistula) and 2 
severe (severe hemorrhage) events; 6 patients developed 
post-surgical endocrine insufficiency (i.e. diabetes). None 
died because of surgical intervention. In this group, 15 
patients (71%) showed no disease recurrence, whereas 
6 patients (28%) presented disease progression after a 
median of 14 months (range 3-58) after surgical resection: 
one had pancreatic recurrence and 5 (83%) had hepatic 
metastatization. All the 6 patients with progressive disease 
underwent SSAs therapy; one patient was subsequently 
administered everolimus therapy, one patient underwent 
peptide receptor radionuclide therapy (PRRT) and one 
underwent percutaneous radiofrequency ablation of liver 
metastases because of further progression disease.
Regarding the ST pNEN group, 5 patients (31%) 
showed disease progression, after a median of 3 months 
(range 1–47) after the first diagnosis. All the patients were 
administered second-line medical therapy, 2 patients were 
treated with PRRT. Four patients died from disease-related 
causes.
DISCUSSION
The present prospective series showed that in terms 
of both OS and PFS the “wait and watch” approach 
appears to be rational and safe when dealing with early-
stage low-grade ø ≤ 20 mm sized well-differentiated 
pNENs, although disease progression may occur also in 
this subset of patients. The optimal management option for 
small (ø ≤20 mm) non-functioning pNENs remains to be 
defined. Based on several retrospective series, the ENETS 
guidelines now recommend a ‘wait and see’ policy for 
selected patients with small asymptomatic pNENs in view 
of their slow growth and good overall survival.
Our prospective study generally confirms the 
opportunity of a conservative approach in these small 
non-functioning pNENs. In fact, both OS and PFS were 
similar in the SR pNEN and FU pNEN groups and only 
one patient experienced disease progression in the FU 
group after 20 months from the initial diagnosis. That 
patient, with MEN-1 syndrome, was initially diagnosed 
with multiple non-functioning pNENs, the largest being ø 
13 mm sized. During the follow-up period she developed 
local progression, nodal and distant metastases, which 
controindicated a surgical approach; she was treated with 
SSAs and is currently alive, with stable disease. The disease 
progression was likely to result from the impredictable 
biological behavior which characterizes pNENs. The 
woman was included in the FU pNEN group in view of 
her tumor features (non-functioning tumor, ø < 2 cm, grade 
1) and because the current management policy for MEN-
1 syndrome suggests a non-operative approach [18–20]. 
In addition, for MEN-1 patients the risk of malignancy 
correlates to the tumor diameter and increases substantially 
when its size approaches or exceeds ø 3 cm [19, 25].
The inclusion of MEN-1 patients which may be 
considered a potentially confounding variable reflects our 
real-life clinical practice. In addition, the distribution of 
MEN-1 cases is homogeneous among the three patient 
groups, thus ruling out any effect on overall results.
Moreover, it should be considered that also the 
patients surgically treated may experience disease 
progression, as occurred in 6 patients of the present series 
(3 of them died because of the disease).
Some factors, more recently described but not 
analyzed in the current series, could be potentially 
predictive of progression, such as the FDG PET status of 
pancreatic lesions [26–27]. In fact, the possible selection 
on the basis of FDG PET would help turning patients 
to surgery rather than to simple follow-up. Noteworthy, 
the identification of prognostic factors of tumor growth 
would be of great help to select for observation only those 
patients with benign and slow-growing tumors.
The strengths of present study include: its 
prospective nature which is of relevance as pertinent data 
from randomized controlled trials are not available, the 
patients’ homogeneous management and follow-up at a 
single treatment centre, and the inclusion of PFS among 
the primary endpoints, besides OS, which is clinically 
more relevant as NENs are known for their generally 
good prognosis. Conversely, our study presents some 
limits, in particular, regarding the small sample size and 
the different tumor stages at presentation of the three 
groups (Table 1), which may affect the results as the three 
compared groups presented different prognostic features, 
i.e. tumor stage and size. In particular an imbalance of 
prognostic patient characteristics is mainly evident among 
FU and SR /ST group. Furthermore, the similar survival 
of FU and SR group may be partially due to the less 
favorable prognostic features of SR group compared to 
FU group. However, the study design (i.e. prospective 
observational study) entails intrinsic limitations which 
could have been avoided only through a randomized trial, 
equally distributing the potentially confounding variables 
among the different groups. Anyway, such study is difficult 
to be designed due to both the rarity of the disease and the 
ethic-related issues. Meanwhile, our observational study, 
despite its intrinsic limitations, may provide preliminary 
information to support the “wait and see” policy, which is 
currently suggested by international guidelines and expert 
opinions [17], even if not properly evidence-based.
On the other hand, the comparison between SR and 
ST groups (well balanced per stage and T size), show a 
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better outcome in SR group respect to ST, confirming the 
positive impact of primary tumour resection on overall 
survival in patient in stage IV. Moreover in the FU pNEN 
group, the staging assessment was performed only through 
morphological and functional imaging, differently from the 
patients undergoing surgery, for which the staging was also 
post-surgical. In the FU pNEN group nodal involvement 
and/or micrometastases might have also been present and not 
detected by imaging techniques: this supporting the possible 
underestimation of disease stage in this cohort, even if in 
this study a worsening survival has not been observed with 
regard to those patients treated with a conservative approach.
Despite the reported limitations, we indeed observed 
that pNENs ø ≤20mm included in the FU group showed 
a 4-year survival rate of 100%, which represents the most 
significant result, demonstrating the safety of such an 
approach.
In summary, on the basis of the present series, 
consideration should be given to a “wait and watch” 
approach to carefully selected small early-stage well-
differentiated non-functioning pNENs, although further 
studies comparing patients with the same prognostic 
characteristics in larger cohort of patients with longer 
follow-up periods are required in order to confirm these 
results.
PATIENTS AND METHODS
Between December 2007 and December 2014, 
51 patients were newly diagnosed with pNENs based 
on clinical data, imaging (computed tomography=CT, 
magnetic resonance imaging= MRI, 68Gallium positron 
emission tomography= Ga-68 PET), ultrasound 
endoscopy, histology. The patients had been consecutively 
enrolled at the Gastroenterology and Endoscopy Unit 
of Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico of Milan, Italy.
The patient characteristics are detailed in Table 
1. Eleven cases (21.6%) presented a functioning tumor: 
6 with gastrinoma, 2 with glucagonoma, one with 
insulinoma, one with VIPoma and one had a pancreatic 
tumor producing serotonin; the remaining 40 patients 
(78.4%) had a non-functioning neoplasm. The tumors were 
staged according to the TMN stage scoring system [22] 
and classified, on the basis of their immunohistochemical 
characteristics according to the WHO 2010 classification, 
as pNENs of grade (G)1 (Ki-67 ≤2%), G2 (Ki-67 3–20%) 
and G3 (Ki-67 >20%) [23].
Chromogranin A (CgA) and specific circulating 
peptides were evaluated at diagnosis and during follow-
up. CgA was measured using a commercially available 
kit (Dako Chromogranin A Elisa Kit, Dako A/S, 
Glostrup, Denmark). A regular clinical, biochemical and 
imaging follow-up was undertaken in all the cases (every 
quarter during the first year and twice a year thereafter). 
Morphological imaging was used to evaluate the objective 
responses (i.e. tumor size) according to the criteria 
released by the Italian Trials in Medical Oncology group 
[24]: classifying as complete, partial (with a tumor size 
decrease of >50%), stable (with a decrease of <50% or an 
increase 25%) and progressive (if the increase was >25%).
Table 1: Demographic and laboratory characteristics of patients with pancreatic neuroendocrine neoplasms 
(pNENs)
Parameter FU (n=15) SR (n=21) ST (n=15)
Male/Female (n) 6/9 7/14 7/8
Age, no. of years 65 (27-84) 52 (27-82) 72 (27-87)

















Size (mm) 11 (7-20) 22 (8-60) 26 (20-60)
Grade (G1/G2/G3) 15/0/0 10/10/1 8/5/2
Functioning yes/no (no. of 
pts) -/15 6/15 5/10
MEN1 (no. of cases) 3 5 2
Follow-up (no. of months) 36 (5-58) 57 (13-84) 27 (2-84)
Chromogranin A (U/L) 40 (12-267) 28 (9-3240) 136 (19-1236)
Data are expressed as median (and range) unless specified otherwise.
G1: neuroendocrine tumor with Ki-67 ≤2%; G2: neuroendocrine tumor with Ki-67 between 3 and 20%; G3: NEN with Ki-
67 >20%
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Among the 51 patients, 15 (male/female 6/9, median 
age 65 years, range 27–84 years) with pNENs ø ≤20 mm 
were proposed for an intensive 3-month follow-up during 
the first year and then on 6-month intervals by CT or MRI 
and every 2 years by Ga-68 PET (FU pNEN group). They 
were all at stage I according to the TNM classification, 
except for one patient (stage IIA). All the patients had a 
well differentiated G1 pNEN. Three patients had a MEN-1 
syndrome.
21 patients (male/female 7/14, median age 52 years, 
range 27–82 years) underwent surgical resection (SR 
pNEN group) because of functioning neoplasms, grade 
>G1, size ø >20 mm. Two patients were at TNM stage 
I, 9 at stage IIA, one at stage IIIB and 9 at stage IV. Ten 
patients had a G1 pNEN, 10 had a G2 pNEN and one 
had a G3 pNEN. Six patients (28.6 %) had a functioning 
tumor; five had a MEN-1 syndrome.
The remaining 15 patients (male/female 7/8, median 
age 72 years, range 27–87 years) received systemic 
therapy (ST pNEN group) because of their advanced 
disease or contraindications to surgery; 5 patients were at 
stage IIA, 2 at stage IIB, 8 at stage IV. Eight patients had 
G1, 5 had G2 and 2 had G3 pNEN. Five patients had a 
functioning tumor, 2 had a MEN-1 syndrome.
All the patients gave their written informed consent 
to the study, which had been approved by the local Ethics 
Committee.
Statistical analysis
All the continuous variables are reported as median 
and range unless stated otherwise. Continuous data were 
analyzed using the non-parametric Mann-Whitney test. 
Differences between percentages were evaluated by χ2 
test.
The survival curves were estimated using the 
Kaplan-Meier method and the log-rank test was used to 
compare the survival curves between different patient 
groups.
Statistical analyses were performed using MedCalc 
sotware and a p value less than 0.05 was considered 
statistically significant.
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